Next Phase Newsletter

An European focused venture capital firm founded in 2015 with partners based in Europe and US. The firm looks for companies mainly in Europe and works closely with the team to expand the business into new markets. The firm invests in series A & series B financings as a Lead or co-Lead with investments ranging from €3 million to €8 million over the life of the company. The firm is actively looking for investment opportunities and plans to make around 12 investments with their new fund over the next 4 years. The firm will only invest in private companies.

The firm is an opportunistic investor and will consider medical devices, diagnostics, and healthcare IT companies. The firm is strongly interested in diagnostics and healthcare IT companies as well as data- analytics and IoT companies. Previous investments include a pharmacogenetic test company and a drug delivery technology platform, clinical trial analytics and others. The firm is very opportunistic in terms of subsectors and indications. For therapeutics, the firm will only consider products that are in phase 2 stage or later. In terms of digital health, the firm has interests in consumer-facing platform and analytics areas, such as big data-driven technologies on complex medical research.

The firm looks for management teams with highly relevant experience and strong industry knowledge is a must. The firm looks for management teams that are willing to work alongside a hands-on investor, and the firm always looks to take a board seat. The firm prefers companies to be backed by strong IP protection and must have already raised seed capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 2015, the investment firm is headquartered in Beijing, managing three venture capital funds in RMB with a total of 1,400 MM RMB (~200MM USD), and is still raising a fund in U.S. dollars of 50MM~100MM USD, with the confirmed limited partners from well-known Chinese big pharma.

The firm has 20+ portfolio companies, and is open to investing globally in the angel to series B round, with a focus on series A round. For therapeutics, the firm is interested in pre-clinical to phase III, mainly the pre-clinical stage. For each fund, the firm selects 10-15 companies to invest in, and each investment ranging from 10MM RMB (1,420,000 USD) to 40MM RMB (5,700,000 USD); the rest of the fund will be used to invest the future rounds of those selected companies to help them grow.

The firm has a general interest in the early-stage life science technology assets, including therapeutics, diagnostics, medical devices, and digital health, especially MRA, Gene diagnostics, AI in healthcare, cell/gene therapy. The firm prefers projects in novel developing areas, but has less interest in technologies that are already in the field of very fierce competition, with big players already in.

The firm has no specific requirements for the Company & Management Team.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A seed fund based in California focuses on applied AI technologies and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A VC firm based in CA invests in companies in Consumer, Enterprise, as well as Life Science & Digital Health. For companies in the life sciences, the firm generally invests in Series seed/A/B rounds, committing between $1-10M in capital. The firm is willing to invest in both the US and China, and will consider companies in pre-clinical and clinical development.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, medtech, Digital Health and R&D services. For therapeutics, the firm will consider traditional therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, medtech, digital health and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services and care management platforms.

The firm looks for companies with a strong management team, large market opportunities and disruptive technology. When investing, the firm is willing to lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Founded in 1982, the private equity firm is based in Boston, MA. The firm has raised 8 funds to date totaling approximately $1 billion in total assets raised. The firm is looking to invest $2-15 million preferred equity in companies with high growth potential. The firm also considers in-licensing of technologies and strategic acquisitions. For equity investments, the firm prefers companies located in the Eastern US and Midwest, but for acquisitions and in-licensing, the firm will consider companies located around the globe. In 2014, The firm launched its Founders Fund through which the firm makes angel investments into high potential, early-stage companies. The Founders Fund typically invests up to $250K in preferred equity.

The firm primarily focuses on the following sectors: Diagnostics (including digital), Pharma Services/Outsourcing, Healthcare IT, and Medical Devices. The firm has a strong preference for companies working with platform technologies. For equity investments, the firm looks for companies that have reached commercialization. With regards to the Founders Fund, the firm primarily seeks companies in healthcare services and SaaS outsourcing businesses.

The firm is looking for experienced management teams with domain expertise and leadership skills that are capable of taking the company to the next value inflection point or additional capital raise. The firm is looking for companies that have at least $2-$30 million in yearly revenue. The firm is interested in company that are profitable or near breakeven and have demonstrated substantial opportunity for growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Founded in 2011, the firm has worked with more than 35 leading healthcare organizations to advance an innovation strategy that supports a culture of idea generation, business creation, and entrepreneurial collaboration in order to drive sustainable impact. In the past, the firm has managed the Intermountain Healthcare Innovation Fund, a $35 million fund closed in 2015 backed by Intermountain Healthcare, with a focus on health technologies with a provider angle. The firm currently manages the DaVita Venture Fund in partnership with DaVita Venture Group, focusing on early-to-mid stage companies that work on transforming healthcare and improving clinical outcomes. Typical size of an initial investment is $1-3 million in Seed to Series B round. The firm can invest up to $5 million over the lifetime of a company. The firm is open to leading or syndicating in a financing round. The firm is currently seeking opportunities globally, but currently has a focus in the U.S.

The firm considers innovations that have a strategic angle to healthcare providers and do not need to go through regulatory development hurdle. Examples may include healthcare operational improvement,

healthcare workflow management, data analytics, radiologic information analysis, telemedicine, population management, and automated screening.

Supporting the interests of the DaVita Venture Fund, the firm is interested in technologies that improve outcomes and quality of care for patients with kidney disease and other chronic diseases. Within the broad life science sectors, the firm will consider pharmaceuticals and medical devices that can help improve clinical outcomes and reduce costs for the healthcare system, with a preference for those with an accelerated regulatory approval pathway. The firm also considers digital health solutions – tech-enabled products and services that leverage technology, data, and connectivity to improve care delivery.

The firm is looking for competent management teams developing innovative solutions to real-world problems in the healthcare industry. The firm’s limited partner, DaVita Venture Group, is actively involved in the vetting process. The firm also prefers companies whose values align with DaVita Venture Group.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A foundation that was established in 1998 and is based in New York, NY. The foundation is currently funding new investment opportunities in the life science space (specifically Alzheimer’s disease and related dementia) through two grants; the Biotechnology Development Program for existing early stage private companies and the Biotechnology Founders Technology Transfer Program supports the establishment of new companies. The foundation typically provides funding of up to $350,000 per year for up to two years for pre-clinical programs or $1-3 M for clinical stage programs. They will invest with other groups for larger deals. The foundation typically provides investments as equity, a convertible loan, and recoverable grants. The foundation will consider investments globally.

The foundation is currently most interested in companies in the therapeutics space but will consider diagnostics if the technology provides significant benefit for Alzheimer’s patients or will accelerate clinical trials. The foundation is interested in both small molecules and biologics and will providing funding from companies anywhere from High throughput screening to Phase IIa of clinical Trials.

The foundation is looking for companies with experienced management teams. The firm looks to be an active value-added investor to help companies with securing future financing rounds when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.